The interactive data dashboard provides an overview of pharmacotherapy treatment in AODTS NMDS in 2020–21 and in the NOPSAD collection on a snapshot day in June 2021 (NOPSAD data does not include Queensland).
In 2020–21, 1.7% of AODTS NMDS treatment episodes provided to clients for their own drug use involved pharmacotherapy as the main treatment type. Among these episodes, the most common principal drug of concern was heroin (46.5% of AODTS NMDS pharmacotherapy episodes).
On a snapshot day in June 2021, 47,563 clients received opioid pharmacotherapy in the NOPSAD collection. The most common pharmacotherapy treatment type was methadone (58.3% of clients) and the most common opioid drug of dependence was heroin (44.3% of NOPSAD clients).
Navigation buttons allow the user to navigate between the following tabs: Overview, Client age and sex, and Treatment.